All of the company's business segments have contributed strongly to the earnings improvement, which shows that the past years' efforts to improve efficiency have paid off.

The company's salt acquisitions are paying off big time thanks to the winter weather.

All in all, the results are better than expected and convincing.

This is a good amendment of Bayer's cardiology and hematology portfolio.

This is a good building block for Bayer.

It's clearly BASF's strategic thinking not to give in and raise the price unless they get some information that justifies it.

This move comes as a surprise, but BASF so far has an excellent track record in acquisitions that were always adding value to investors.

Strengthening their product range further down the value chain makes a lot of sense.

The results were in line. The chemicals cycle is humming right now. The high dividend is not surprising, seeing the growth in profit.

I think Engelhard is opening up to a friendly transaction.